Status:
UNKNOWN
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects
Lead Sponsor:
Jagiellonian University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of the current study is to evaluate whether treatment with high doses of simvastatin can reduce coagulation activation in patients with acute coronary syndromes and if ezetimibe in conjunction...
Detailed Description
Clinical status will be evaluated during hospitalization, and then on the out-patient basis. All cardiovascular events (fatal or nonfatal myocardial infarction, unstable angina, sudden cardiac death, ...
Eligibility Criteria
Inclusion
- Age \< 75 years
- Acute coronary syndrome (symptom onset \< 12 h)
Exclusion
- Diabetes on insulin
- Anticoagulant therapy
- Renal insufficiency
- Liver injury
- Acute cardiovascular event within the previous 3 months
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00725829
Start Date
June 1 2008
End Date
December 1 2009
Last Update
February 10 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiology
Krakow, Poland, 31202